Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | THPO | P40225 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 6/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3285034 | 1.00 | CYP2D6 (0.56) | CYP2D6ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL3285493 | 1.00 | CYP2D6 (0.56) | CYP2D6ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL3283614 | 0.77 | HTR2C (0.53) | CYP2D6ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL3283933 | 0.77 | HTR2C (0.53) | CYP2D6ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL3286362 | 0.77 | HTR2C (0.53) | CYP2D6ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL8028688 | 0.77 | ADRA2A (0.50) | CYP2D6ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL9541303 | 0.73 | ADRA2A (0.43) | CYP2D6ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL2276424 | 0.73 | PRCP (0.53) | HTR2CTHPOHSD17B10HIF1ADRD1 | |
| SCHEMBL8083358 | 0.72 | ADRA2A (1.00) | CYP2D6ADRA2AADRA2BADRA2CADRA1D | |
| Hydrochloric Acid SCHEMBL7568493 | 0.71 | SIGMAR1 (0.54) | THPOHSD17B10HIF1ADRD1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3733204-A1 | THERAPEUTIC AGENT FOR STRESS URINARY INCONTINENCE AND FECAL INCONTINENCE | Takeda Pharmaceutical Company Limited (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-20130172322-A1 | BENZAZEPINE DERIVATIVES USEFUL FOR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. | 2013-07-04 | — | — | US | disclosed |
| US-8404675-B2 | Benzazepine derivatives and methods of prophylaxis or treatment of 5HT2C receptor associated diseases | ARENA PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20100173894-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. | 2010-07-08 | — | — | US | disclosed |
| US-7704993-B2 | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20070142357-A1 | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-06-21 | — | — | US | disclosed |
| EP-1633720-A1 | BENZAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | Arena Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005003096-A1 | BENZAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173894-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | HTR2C, TPH2, HTR2A | CYP2D6 305/4885ADRA2A 47/4885ADRA2B 44/4885 |
| US-20130172322-A1 | BENZAZEPINE DERIVATIVES USEFUL FOR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | HTR2C, HTR2A, TPH2 | CYP2D6 386/4885ADRA2A 37/4885ADRA2B 40/4885 |
| US-20070142357-A1 | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | HTR2C, TPH2, HTR2A | CYP2D6 305/4885ADRA2A 47/4885ADRA2B 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.